QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:PRVB

Provention Bio (PRVB) Stock Forecast, Price & News

$4.21
+0.08 (+1.94%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.03
$4.23
50-Day Range
$3.71
$7.88
52-Week Range
$3.40
$11.49
Volume
848,860 shs
Average Volume
853,794 shs
Market Capitalization
$269.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.74
30 days | 90 days | 365 days | Advanced Chart
Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter.

Provention Bio logo

About Provention Bio

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Headlines

Provention Bio Inc. Tops Q1 EPS by 11c
Provention Bio Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRVB
Fax
N/A
Employees
82
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$1.47 per share

Profitability

Net Income
$-114.43 million
Pretax Margin
-5,671.70%

Debt

Price-To-Earnings

Miscellaneous

Free Float
55,651,000
Market Cap
$269.61 million
Optionable
Not Optionable

Company Calendar

Last Earnings
2/24/2022
Today
5/16/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

687th out of 1,423 stocks

Pharmaceutical Preparations Industry

324th out of 678 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

Is Provention Bio a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Provention Bio stock.
View analyst ratings for Provention Bio
or view top-rated stocks.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Provention Bio
.

How were Provention Bio's earnings last quarter?

Provention Bio, Inc. (NASDAQ:PRVB) released its quarterly earnings data on Thursday, February, 24th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.03. The company earned $0.72 million during the quarter, compared to analyst estimates of $0.71 million. During the same quarter in the previous year, the company posted ($0.58) earnings per share.
View Provention Bio's earnings history
.

What price target have analysts set for PRVB?

8 brokerages have issued 12-month price targets for Provention Bio's shares. Their forecasts range from $8.00 to $25.00. On average, they expect Provention Bio's share price to reach $17.50 in the next year. This suggests a possible upside of 315.7% from the stock's current price.
View analysts' price targets for Provention Bio
or view top-rated stocks among Wall Street analysts.

Who are Provention Bio's key executives?
Provention Bio's management team includes the following people:
  • Mr. Ashleigh W. Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 59, Pay $874.15k) (LinkedIn Profile)
  • Dr. Francisco Leon M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 50, Pay $603k) (LinkedIn Profile)
  • Dr. Eleanor L. Ramos, Chief Medical Officer (Age 66, Pay $635.6k) (LinkedIn Profile)
  • Mr. Andrew T. Drechsler, Special Advisor (Age 50, Pay $589.4k)
  • Mr. Jason Hoitt, Chief Commercial Officer (Age 44, Pay $591.33k)
  • Mr. Thierry Chauche, Chief Financial Officer
  • Ms. Christina Yi, Chief Operations Officer
  • Mr. Robert A. Doody Jr., VP of Investor Relations
  • Ms. Heidy Abreu King-Jones J.D., L.L.M., Chief Legal Officer (Age 39)
  • Dr. Sherron Kell, Sr. VP of Clinical Devel.
What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV).

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.86%), Vanguard Group Inc. (3.98%), State Street Corp (1.99%), Verition Fund Management LLC (1.70%), DG Capital Management LLC (0.82%) and Northern Trust Corp (0.81%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos and Francisco Leon.
View institutional ownership trends for Provention Bio
.

Which institutional investors are selling Provention Bio stock?

PRVB stock was sold by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, DG Capital Management LLC, BlackRock Inc., Northern Trust Corp, Group One Trading L.P., Bank of New York Mellon Corp, Raymond James & Associates, and Citigroup Inc..
View insider buying and selling activity for Provention Bio
or view top insider-selling stocks.

Which institutional investors are buying Provention Bio stock?

PRVB stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., 1900 Wealth Management LLC, State Street Corp, Vanguard Group Inc., Nisa Investment Advisors LLC, HAP Trading LLC, MetLife Investment Management LLC, and HighTower Advisors LLC. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, and Francisco Leon.
View insider buying and selling activity for Provention Bio
or or view top insider-buying stocks.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $4.21.

How much money does Provention Bio make?

Provention Bio has a market capitalization of $269.61 million and generates $1.39 million in revenue each year. The company earns $-114.43 million in net income (profit) each year or ($1.650010) on an earnings per share basis.

How many employees does Provention Bio have?

Provention Bio employs 82 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at (908) 428-9136 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.